EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurrence: A United States (US) Payer Perspective

Abstract

To estimate, from a US payer perspective, the cost-utility of adjuvant treatment of UC after radical resection with nivolumab versus observation using data with 11 months’ minimum follow-up from the Phase 3 CheckMate-274 trial and survival estimates from the published literature.